Home Tools
Log in
Cart

Cetuximab

Catalog No. T9905   CAS 205923-56-4
Synonyms: Cetuximab (anti-EGFR), C225

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Cetuximab Chemical Structure
Cetuximab, CAS 205923-56-4
Pack Size Availability Price/USD Quantity
1 mg In stock $ 197.00
2 mg In stock $ 289.00
5 mg In stock $ 482.00
10 mg In stock $ 697.00
25 mg In stock $ 1,090.00
50 mg In stock $ 1,470.00
100 mg In stock $ 1,980.00
Bulk Inquiry
Get quote
Select Batch  
AntibodyUnit: 5 mg/mL
Purity: 100.00%
AntibodyUnit: 5 mg/mL
Purity: 100.00%
AntibodyUnit: 5 mg/mL
Purity: 98.60%
AntibodyUnit: 5.2 mg/mL
Purity: 98.00%
AntibodyUnit: 5 mg/mL
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
Targets&IC50 EGFR:0.147 nM (Kd, Fixed A431 cells) , EGFR:0.201 nM (Kd)
In vitro METHODS: Human squamous cell carcinoma (SCC) cells SCC-13Y, SCC-38, SCC-1, and SCC-11B were treated with Cetuximab (30 nM) for 8 days, and cell numbers were measured using a hemacytometer.
RESULTS: Cetuximab inhibited cell proliferation of SCC cells in a time-dependent manner. Cetuximab inhibited the growth of SCC cell lines in a time-dependent manner, ranging from 20%-75% compared to untreated controls. [1]
METHODS: EGFR mutant cells PC-9 and EGFR wild-type cells PC-14, A549 were treated with Cetuximab (10-100 µg/mL) for 24 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: EGFR phosphorylation was strongly expressed in PC-9 and continued to be strongly expressed during Cetuximab treatment.In PC-14 and A549 cells, although the increase in EGFR phosphorylation was reduced by the addition of Cetuximab, phosphorylation was not completely inhibited at the highest concentration. [2]
In vivo METHODS: To assay antitumor activity in vivo, Cetuximab (1 mg/injection) was administered intraperitoneally to BALB/c (nu/nu) mice harboring HNSCC tumors UT-SCC-2 or UT-SCC-14 on the 10th, 13th, and 16th days after tumor cell injection.
RESULTS: Cetuximab treatment reduced tumor growth in HNSCC xenografts and increased local oxygen partial pressure in tumors. [3]
METHODS: To study in vivo antitumor activity, Cetuximab (0.25-1 mg/mouse) was administered intraperitoneally to nude mice bearing xenograft tumors every three days for a minimum of five injections.
RESULTS: Treatment with Cetuximab alone effectively delayed the growth of GEO and L2987 tumors for at least 10 days. Borderline activity was observed in A549 and WiDr xenografts. However, Cetuximab did not show any significant anti-tumor activity in HT29, HCT116, LOVO, Colo205, LX-1, HCC70 and N87 models. [4]
Synonyms Cetuximab (anti-EGFR), C225
Molecular Weight 152 kDa
Formula C107H179N35O36S7
CAS No. 205923-56-4

Storage

store at low temperature

store at -20°C

TargetMolReferences and Literature

1. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40. 2. Kimura H, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007 Aug;98(8):1275-80. 3. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Dec;75(3-4):299-309. 4. Wild R, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther. 2006 Jan;5(1):104-13.

TargetMolCitations

1. Komatsu M, Nakamura K, Takeda T, et al. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling. Oncogene. 2022: 1-14.

Related Products

Related compounds with same targets
EMI1 EBE-A22 Tucatinib Panitumumab O-Desmethyl gefitinib D8 Naluzotan hydrochloride Norcantharidin CP-380736

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Dosage
mg/kg
Average weight of animals
g
Dosing volume per animal
ul
Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
Calculate Reset

TargetMolCalculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
=
X
X

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

X
=
X

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

=
/

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Cetuximab 205923-56-4 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Inhibitor Epidermal growth factor receptor ErbB-1 inhibit Cetuximab (anti-EGFR) C225 C-225 C 225 anti-EGFR HER1 inhibitor

 

TargetMol